Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trivalent HPV16/18/58 vaccine (E. coli) dose-ranging in healthy Chinese women
CTR20180525Phase 2Completed
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Apr 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant trivalent human papillomavirus (types 16/18/58) vaccine in HPV16 infection (HPV16), human papillomavirus infection type 18, human papillomavirus infection, Cervical Cancer (CC), sponsored by Beijing Konruns Pharmaceutical Co., Ltd.. Started Apr 2018; status: completed.
02
Drugs
recombinant trivalent human papillomavirus (types 16/18/58) vaccine
03
Conditions
HPV16 infection (HPV16)human papillomavirus infection type 18human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on CTR20180525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180525.